Korean biotech & pharma: who is buying?
Foreign, institutional and retail net flows for 120 KOSPI and KOSDAQ biotech and pharmaceutical companies, sorted by 20-session foreign net buying. Data as of Oct 16, 2026.
Summary
Over the last 20 trading sessions foreign investors net sold ₩528.4bn ($393M) of the 120 biotech and pharma stocks covered here, with net buying in 45 of them. Institutions net bought ₩333.8bn and retail investors net bought ₩57.8bn over the same window. The largest foreign purchases were Pharma Research, Alteogen, Seegene. The largest foreign sales were Samsung Biologics, HLB, Sam Chun Dang Pharm. Foreign investors own 9.3% of the average company in this group (simple average of KRX ownership ratios).
Korean biotech is where foreign flows matter most: licensing deals with global pharma, U.S. FDA milestones and index inclusion decisions are announced in English, but the daily KRX data on who is actually buying the shares is published only in Korean. Each company below links to a page with its full flow history, foreign ownership trend and financials.
| Company | Ticker | Market | Market cap | Foreign own. | Fwd P/E | Foreign 1d | Foreign 5d | Foreign 20d | (USD 20d) | Institutions 20d | Retail 20d |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharma Research 파마리서치 | 214450 | KOSDAQ | ₩3T ($2.1B) | 15.69% | 11.9× | ₩-0.8bn | +₩53.2bn | +₩130.1bn | +$97M | ₩-126.2bn | ₩-1.3bn |
| Alteogen 알테오젠 | 196170 | KOSDAQ | ₩16T ($12.1B) | 16.04% | 45.1× | +₩40.0bn | +₩133.4bn | +₩121.2bn | +$90M | +₩41.1bn | ₩-159.7bn |
| Seegene 씨젠 | 096530 | KOSDAQ | ₩2T ($1.3B) | 24.08% | 17.8× | +₩1.6bn | +₩6.7bn | +₩43.0bn | +$32M | +₩11.6bn | ₩-54.6bn |
| ABL Bio 에이비엘바이오 | 298380 | KOSDAQ | ₩2T ($1.8B) | 14.56% | 234.5× | +₩4.7bn | +₩5.9bn | +₩39.0bn | +$29M | ₩-45.7bn | +₩11.5bn |
| Celltrion 셀트리온 | 068270 | KOSPI | ₩45T ($33.5B) | 25.29% | 26.1× | +₩82.2bn | +₩67.2bn | +₩38.5bn | +$29M | +₩169.3bn | ₩-304.2bn |
| ST Pharm 에스티팜 | 237690 | KOSDAQ | ₩2T ($1.4B) | 13.58% | 22.0× | +₩4.5bn | +₩8.9bn | +₩17.6bn | +$13M | ₩-7.4bn | ₩-13.2bn |
| Yuhan 유한양행 | 000100 | KOSPI | ₩6T ($4.4B) | 21.39% | 30.4× | +₩11.9bn | +₩19.8bn | +₩10.2bn | +$8M | +₩10.1bn | ₩-20.3bn |
| JS Link 제이에스링크 | 127120 | KOSDAQ | ₩1T ($0.6B) | 4.34% | – | +₩2.0bn | +₩7.6bn | +₩8.4bn | +$6M | +₩10.6bn | ₩-20.5bn |
| Hanall Biopharma 한올바이오파마 | 009420 | KOSPI | ₩2T ($1.6B) | 4.72% | 2347.9× | +₩1.1bn | +₩5.5bn | +₩8.2bn | +$6M | ₩-22.1bn | +₩11.1bn |
| GC Genome 지씨지놈 | 340450 | KOSDAQ | ₩0T ($0.2B) | 6.51% | 30.9× | ₩-0.4bn | +₩3.0bn | +₩7.1bn | +$5M | +₩6.3bn | ₩-13.9bn |
| D&D Pharmatech 디앤디파마텍 | 347850 | KOSDAQ | ₩2T ($1.3B) | 10.57% | – | +₩2.3bn | +₩11.3bn | +₩5.7bn | +$4M | ₩-10.4bn | +₩3.7bn |
| Ildong Pharm 일동제약 | 249420 | KOSPI | ₩0T ($0.3B) | 5.41% | – | +₩1.9bn | +₩2.9bn | +₩5.0bn | +$4M | ₩-0.0bn | ₩-5.0bn |
| In Body 인바디 | 041830 | KOSDAQ | ₩1T ($0.5B) | 33.83% | 11.5× | ₩-0.4bn | +₩1.7bn | +₩4.8bn | +$4M | +₩5.9bn | ₩-9.5bn |
| Onconic Therapeutics 온코닉테라퓨틱스 | 476060 | KOSDAQ | ₩1T ($0.5B) | 0.51% | 20.8× | +₩1.9bn | +₩3.9bn | +₩4.6bn | +$3M | ₩-0.6bn | ₩-4.2bn |
| Orum Therapeutics 오름테라퓨틱 | 475830 | KOSDAQ | ₩0T ($0.3B) | 7.93% | – | +₩1.0bn | +₩2.9bn | +₩4.3bn | +$3M | ₩-17.0bn | +₩13.1bn |
| Peptron 펩트론 | 087010 | KOSDAQ | ₩2T ($1.7B) | 4.51% | – | +₩11.0bn | +₩12.4bn | +₩4.2bn | +$3M | ₩-16.1bn | +₩6.9bn |
| SK Bioscience SK바이오사이언스 | 302440 | KOSPI | ₩3T ($2.1B) | 6.2% | – | +₩1.8bn | +₩2.1bn | +₩3.9bn | +$3M | ₩-2.7bn | ₩-1.5bn |
| Shinpoong Pharmaceutical 신풍제약 | 019170 | KOSPI | ₩1T ($0.4B) | 4.57% | – | +₩2.3bn | +₩3.9bn | +₩3.8bn | +$3M | ₩-0.2bn | ₩-3.8bn |
| Celltrion Pharm 셀트리온제약 | 068760 | KOSDAQ | ₩2T ($1.3B) | 4.85% | 37.6× | +₩2.3bn | +₩0.9bn | +₩3.4bn | +$3M | ₩-7.7bn | +₩4.3bn |
| Hyundai pharm 현대약품 | 004310 | KOSPI | ₩0T ($0.2B) | 2.08% | – | +₩0.0bn | +₩1.8bn | +₩3.2bn | +$2M | +₩0.0bn | ₩-3.4bn |
| Jwpharmaceutical JW중외제약 | 001060 | KOSPI | ₩1T ($0.4B) | 7.9% | – | +₩0.5bn | +₩2.0bn | +₩3.1bn | +$2M | +₩0.5bn | ₩-3.6bn |
| Komipharm International 코미팜 | 041960 | KOSDAQ | ₩1T ($0.6B) | 4.75% | – | +₩0.1bn | ₩-0.7bn | +₩3.0bn | +$2M | ₩-1.1bn | ₩-1.7bn |
| Aimed Bio 에임드바이오 | 0009K0 | KOSDAQ | ₩1T ($1.0B) | 2.96% | – | +₩0.9bn | +₩0.1bn | +₩2.9bn | +$2M | ₩-0.6bn | ₩-2.4bn |
| Samyang Biopharm 삼양바이오팜 | 0120G0 | KOSPI | ₩0T ($0.2B) | 3.57% | – | +₩1.0bn | +₩0.6bn | +₩2.8bn | +$2M | ₩-1.0bn | ₩-1.4bn |
| Naturecell 네이처셀 | 007390 | KOSDAQ | ₩1T ($1.0B) | 7.49% | – | ₩-1.3bn | ₩-1.0bn | +₩2.4bn | +$2M | ₩-0.1bn | ₩-2.3bn |
| Tomocube 토모큐브 | 475960 | KOSDAQ | ₩0T ($0.3B) | 2.27% | 33.4× | +₩0.1bn | +₩1.1bn | +₩2.2bn | +$2M | +₩2.4bn | ₩-4.7bn |
| Tool Gen Incorporated 툴젠 | 199800 | KOSDAQ | ₩0T ($0.2B) | 2.7% | – | +₩0.1bn | ₩-0.3bn | +₩2.1bn | +$2M | ₩-3.4bn | +₩1.4bn |
| Vieworks 뷰웍스 | 100120 | KOSDAQ | ₩0T ($0.2B) | 30.83% | 6.9× | ₩-0.1bn | +₩1.2bn | +₩1.7bn | +$1M | +₩0.1bn | ₩-2.1bn |
| Chongkundang 종근당 | 185750 | KOSPI | ₩1T ($0.7B) | 15.73% | 12.2× | +₩1.4bn | +₩3.0bn | +₩1.6bn | +$1M | +₩0.3bn | ₩-2.0bn |
| JVM 제이브이엠 | 054950 | KOSDAQ | ₩0T ($0.2B) | 20.36% | 7.4× | +₩0.1bn | +₩1.2bn | +₩1.4bn | +$1M | +₩0.3bn | ₩-1.4bn |
| Caregen 케어젠 | 214370 | KOSDAQ | ₩2T ($1.6B) | 4.72% | – | +₩1.0bn | +₩3.2bn | +₩1.3bn | +$1M | +₩0.6bn | ₩-3.6bn |
| Kolon Tissue Gene 코오롱티슈진 | 950160 | KOSDAQ | ₩1T ($0.9B) | 3.96% | – | +₩1.2bn | ₩-0.2bn | +₩0.9bn | +$1M | ₩-0.7bn | +₩0.1bn |
| Wontech 원텍 | 336570 | KOSDAQ | ₩0T ($0.3B) | 3.38% | 7.3× | +₩0.8bn | +₩0.8bn | +₩0.8bn | +$1M | +₩0.4bn | ₩-1.2bn |
| SD Biosensor 에스디바이오센서 | 137310 | KOSPI | ₩1T ($0.6B) | 6.09% | – | +₩0.3bn | +₩0.7bn | +₩0.8bn | +$1M | +₩0.9bn | ₩-1.4bn |
| HLB Life Science HLB생명과학 | 067630 | KOSDAQ | ₩0T ($0.3B) | 5.91% | – | ₩-0.2bn | ₩-0.3bn | +₩0.7bn | +$1M | ₩-0.2bn | ₩-0.3bn |
| Samjin Pharmaceutical 삼진제약 | 005500 | KOSPI | ₩0T ($0.2B) | 3.83% | 10.6× | +₩0.1bn | +₩0.5bn | +₩0.6bn | +$0M | ₩-0.1bn | ₩-0.4bn |
| Pharmicell 파미셀 | 005690 | KOSPI | ₩1T ($0.5B) | 8.51% | 9.2× | +₩0.8bn | ₩-0.2bn | +₩0.5bn | +$0M | +₩4.8bn | ₩-5.7bn |
| GC 녹십자홀딩스 | 005250 | KOSPI | ₩0T ($0.3B) | 8.12% | – | +₩0.4bn | +₩0.9bn | +₩0.5bn | +$0M | ₩-0.1bn | ₩-0.5bn |
| Genomictree 지노믹트리 | 228760 | KOSDAQ | ₩0T ($0.2B) | 2.44% | – | +₩0.5bn | +₩0.9bn | +₩0.3bn | +$0M | ₩-2.4bn | +₩1.8bn |
| Qurient 큐리언트 | 115180 | KOSDAQ | ₩1T ($0.6B) | 3.15% | – | ₩-0.6bn | ₩-0.6bn | +₩0.3bn | +$0M | ₩-1.9bn | ₩-0.3bn |
| Medipost 메디포스트 | 078160 | KOSDAQ | ₩0T ($0.3B) | 2.54% | – | ₩0.0bn | ₩-0.1bn | +₩0.3bn | +$0M | +₩0.1bn | ₩-0.5bn |
| Prestige Biopharma Limited Kdr 프레스티지바이오파마 | 950210 | KOSPI | ₩0T ($0.3B) | 63.68% | – | +₩0.1bn | +₩0.1bn | +₩0.3bn | +$0M | +₩0.0bn | ₩-0.2bn |
| curacle 큐라클 | 365270 | KOSDAQ | ₩0T ($0.2B) | 1.92% | – | +₩0.4bn | +₩0.3bn | +₩0.2bn | +$0M | +₩0.1bn | ₩-0.6bn |
| i-SENS 아이센스 | 099190 | KOSDAQ | ₩0T ($0.4B) | 24.49% | 38.6× | +₩0.5bn | +₩0.6bn | +₩0.2bn | +$0M | +₩0.4bn | ₩-0.8bn |
| Hans Biomed 한스바이오메드 | 042520 | KOSDAQ | ₩0T ($0.2B) | 6% | 12.2× | +₩0.9bn | +₩0.2bn | +₩0.1bn | +$0M | +₩3.7bn | ₩-3.7bn |
| It-chem 아이티켐 | 309710 | KOSDAQ | ₩0T ($0.2B) | 0% | – | ₩0.0bn | ₩0.0bn | ₩0.0bn | $0M | ₩0.0bn | ₩0.0bn |
| NK Gen Biotech Korea 엔케이젠바이오텍코리아 | 182400 | KOSDAQ | ₩0T ($0.2B) | 0% | – | ₩0.0bn | ₩0.0bn | ₩0.0bn | $0M | ₩0.0bn | ₩0.0bn |
| GC Biopharma 녹십자 | 006280 | KOSPI | ₩1T ($1.1B) | 23.65% | 19.4× | +₩1.8bn | +₩1.4bn | ₩-0.0bn | $-0M | +₩1.8bn | ₩-3.0bn |
| Bio Note 바이오노트 | 377740 | KOSPI | ₩0T ($0.4B) | 0.52% | – | +₩0.1bn | +₩0.2bn | ₩-0.0bn | $-0M | +₩0.1bn | ₩-0.1bn |
| Hyundai Bioscience 현대바이오 | 048410 | KOSDAQ | ₩1T ($0.5B) | 6.11% | – | +₩1.1bn | ₩-0.0bn | ₩-0.0bn | $-0M | ₩-0.4bn | +₩1.8bn |
| Suheung 서흥 | 008490 | KOSPI | ₩0T ($0.2B) | 6.44% | – | +₩0.1bn | +₩0.4bn | ₩-0.1bn | $-0M | ₩-0.7bn | +₩0.6bn |
| Bukwang Pharmaceutical 부광약품 | 003000 | KOSPI | ₩0T ($0.3B) | 6.8% | – | +₩0.5bn | ₩-0.4bn | ₩-0.1bn | $-0M | ₩-1.3bn | +₩1.4bn |
| Dx & Vx DXVX | 180400 | KOSDAQ | ₩0T ($0.2B) | 4.94% | – | ₩-0.0bn | +₩0.1bn | ₩-0.1bn | $-0M | ₩0.0bn | +₩0.0bn |
| Ilsung Is 일성아이에스 | 003120 | KOSPI | ₩0T ($0.2B) | 0.32% | – | +₩0.0bn | +₩0.2bn | ₩-0.1bn | $-0M | +₩0.0bn | +₩0.0bn |
| Du Chem Bio 듀켐바이오 | 176750 | KOSDAQ | ₩0T ($0.2B) | 0.8% | – | ₩-0.1bn | +₩0.1bn | ₩-0.1bn | $-0M | ₩0.0bn | +₩1.3bn |
| Daewoongpharmaceutical 대웅제약 | 069620 | KOSPI | ₩1T ($0.9B) | 14.82% | 6.3× | +₩0.5bn | +₩2.1bn | ₩-0.1bn | $-0M | ₩-2.8bn | +₩2.4bn |
| Korea United Pharm 유나이티드제약 | 033270 | KOSPI | ₩0T ($0.2B) | 8.7% | 6.6× | +₩0.2bn | +₩0.3bn | ₩-0.3bn | $-0M | ₩-0.1bn | +₩0.3bn |
| Silla Jen 신라젠 | 215600 | KOSDAQ | ₩0T ($0.2B) | 2.83% | – | +₩0.2bn | +₩0.4bn | ₩-0.3bn | $-0M | ₩-0.1bn | +₩0.3bn |
| INFINITT Healthcare 인피니트헬스케어 | 071200 | KOSDAQ | ₩0T ($0.2B) | 13.19% | – | +₩0.1bn | +₩0.5bn | ₩-0.3bn | $-0M | +₩7.9bn | ₩-9.8bn |
| Liga Chem Biosciences 리가켐바이오 | 141080 | KOSDAQ | ₩3T ($1.9B) | 12.97% | – | +₩4.3bn | +₩14.9bn | ₩-0.3bn | $-0M | ₩-34.8bn | +₩31.0bn |
| Dentium 덴티움 | 145720 | KOSPI | ₩0T ($0.3B) | 13.46% | 5.6× | +₩0.5bn | ₩-0.2bn | ₩-0.3bn | $-0M | +₩3.9bn | ₩-3.8bn |
| Humedix 휴메딕스 | 200670 | KOSDAQ | ₩0T ($0.2B) | 6.55% | 6.1× | +₩0.4bn | +₩0.1bn | ₩-0.4bn | $-0M | +₩0.1bn | +₩0.4bn |
| HEM Pharma HEM파마 | 376270 | KOSDAQ | ₩0T ($0.2B) | 0.44% | – | +₩0.2bn | +₩0.2bn | ₩-0.4bn | $-0M | +₩0.0bn | +₩0.5bn |
| Kwangdong Pharmaceutical 광동제약 | 009290 | KOSPI | ₩0T ($0.3B) | 15.97% | – | +₩0.1bn | +₩1.1bn | ₩-0.4bn | $-0M | ₩-0.1bn | +₩0.5bn |
| Donga ST 동아에스티 | 170900 | KOSPI | ₩0T ($0.3B) | 19.29% | 10.3× | +₩0.2bn | ₩-0.1bn | ₩-0.4bn | $-0M | ₩-0.1bn | +₩0.3bn |
| Eu Biologics 유바이오로직스 | 206650 | KOSDAQ | ₩0T ($0.2B) | 5.88% | – | +₩0.4bn | +₩0.7bn | ₩-0.4bn | $-0M | ₩0.0bn | +₩0.3bn |
| Into Cell 인투셀 | 287840 | KOSDAQ | ₩0T ($0.2B) | 4.69% | – | +₩0.4bn | +₩0.7bn | ₩-0.5bn | $-0M | ₩-0.3bn | +₩0.6bn |
| Myungin Pharm 명인제약 | 317450 | KOSPI | ₩1T ($0.4B) | 0.76% | – | +₩0.2bn | ₩-0.2bn | ₩-0.5bn | $-0M | ₩-0.9bn | +₩1.4bn |
| Bio Plus 바이오플러스 | 099430 | KOSDAQ | ₩0T ($0.2B) | 2.99% | – | +₩0.1bn | +₩0.2bn | ₩-0.6bn | $-0M | +₩0.0bn | ₩-1.0bn |
| Curexo 큐렉소 | 060280 | KOSDAQ | ₩0T ($0.2B) | 4.84% | 40.7× | +₩0.4bn | +₩0.7bn | ₩-0.6bn | $-0M | ₩-1.2bn | +₩1.8bn |
| GI Innovation 지아이이노베이션 | 358570 | KOSDAQ | ₩0T ($0.4B) | 8.85% | – | +₩0.3bn | ₩-1.3bn | ₩-0.7bn | $-1M | +₩1.0bn | ₩-0.9bn |
| Jetema 제테마 | 216080 | KOSDAQ | ₩0T ($0.2B) | 2.24% | 133.1× | ₩-0.1bn | ₩-0.2bn | ₩-0.7bn | $-1M | ₩-0.7bn | +₩1.1bn |
| S.Biomedics 에스바이오메딕스 | 304360 | KOSDAQ | ₩0T ($0.2B) | 1.69% | – | +₩0.2bn | ₩-0.1bn | ₩-0.8bn | $-1M | +₩0.1bn | +₩0.8bn |
| Rokit Healthcare 로킷헬스케어 | 376900 | KOSDAQ | ₩0T ($0.3B) | 5.82% | – | +₩0.7bn | +₩2.5bn | ₩-0.8bn | $-1M | ₩-1.5bn | +₩3.0bn |
| Gc Cell 지씨셀 | 144510 | KOSDAQ | ₩0T ($0.2B) | 2.8% | – | +₩0.1bn | ₩-0.2bn | ₩-0.9bn | $-1M | ₩-0.0bn | +₩0.9bn |
| Huons 휴온스 | 243070 | KOSDAQ | ₩0T ($0.2B) | 15.7% | – | +₩0.2bn | +₩0.3bn | ₩-1.0bn | $-1M | +₩0.2bn | +₩0.8bn |
| Penetrium Bio 페니트리움바이오 | 187660 | KOSDAQ | ₩0T ($0.3B) | 0.54% | – | ₩-0.2bn | ₩-0.0bn | ₩-1.2bn | $-1M | +₩0.0bn | +₩1.3bn |
| Curocell 큐로셀 | 372320 | KOSDAQ | ₩0T ($0.3B) | 1.32% | – | +₩0.2bn | +₩0.3bn | ₩-1.2bn | $-1M | ₩-0.0bn | +₩1.1bn |
| Nextbiomedical 넥스트바이오메디컬 | 389650 | KOSDAQ | ₩0T ($0.2B) | 1.64% | 71.6× | +₩0.2bn | +₩0.3bn | ₩-1.3bn | $-1M | +₩0.6bn | +₩0.8bn |
| T&L 티앤엘 | 340570 | KOSDAQ | ₩0T ($0.3B) | 13.01% | 6.5× | +₩0.2bn | +₩3.5bn | ₩-1.5bn | $-1M | +₩4.2bn | ₩-1.9bn |
| Cosmax Bti 코스맥스비티아이 | 044820 | KOSPI | ₩0T ($0.2B) | 5.21% | – | ₩-0.2bn | ₩-0.9bn | ₩-1.5bn | $-1M | +₩3.1bn | ₩-1.8bn |
| Medy-Tox 메디톡스 | 086900 | KOSDAQ | ₩0T ($0.4B) | 12.14% | 14.4× | +₩1.1bn | +₩1.4bn | ₩-1.5bn | $-1M | +₩0.2bn | +₩1.1bn |
| Bioneer 바이오니아 | 064550 | KOSDAQ | ₩0T ($0.2B) | 3.61% | – | +₩0.8bn | +₩1.5bn | ₩-1.5bn | $-1M | +₩0.1bn | +₩1.3bn |
| Stcube 에스티큐브 | 052020 | KOSDAQ | ₩1T ($0.4B) | 5.5% | – | +₩0.0bn | ₩-0.1bn | ₩-1.5bn | $-1M | ₩-0.0bn | +₩1.8bn |
| Boryung 보령 | 003850 | KOSPI | ₩1T ($0.5B) | 4.89% | 10.7× | +₩0.2bn | +₩0.4bn | ₩-1.8bn | $-1M | +₩3.1bn | ₩-1.2bn |
| Value Added Technology 바텍 | 043150 | KOSDAQ | ₩0T ($0.2B) | 21.14% | 4.5× | +₩0.1bn | ₩-0.1bn | ₩-1.9bn | $-1M | ₩-0.0bn | +₩1.7bn |
| Daewoong 대웅 | 003090 | KOSPI | ₩1T ($0.7B) | 4.96% | – | +₩0.5bn | +₩0.3bn | ₩-2.1bn | $-2M | ₩-0.3bn | +₩2.4bn |
| Future Chem 퓨쳐켐 | 220100 | KOSDAQ | ₩0T ($0.2B) | 4.87% | – | +₩0.2bn | ₩-0.0bn | ₩-2.2bn | $-2M | ₩-2.2bn | +₩4.2bn |
| IM Biologics 아이엠바이오로직스 | 493280 | KOSDAQ | ₩0T ($0.2B) | 2.86% | – | +₩0.2bn | ₩-0.4bn | ₩-2.7bn | $-2M | ₩-1.2bn | +₩4.5bn |
| Hlb Pharmaceutical HLB제약 | 047920 | KOSDAQ | ₩0T ($0.3B) | 0.53% | – | +₩0.2bn | ₩-0.4bn | ₩-2.9bn | $-2M | ₩-10.1bn | +₩12.9bn |
| Genome&Company 지놈앤컴퍼니 | 314130 | KOSDAQ | ₩0T ($0.2B) | 2.56% | – | ₩-0.7bn | ₩-0.9bn | ₩-2.9bn | $-2M | ₩-3.3bn | +₩7.8bn |
| HLB Therapeutics HLB테라퓨틱스 | 115450 | KOSDAQ | ₩0T ($0.2B) | 2.61% | – | ₩-0.2bn | ₩-0.5bn | ₩-3.1bn | $-2M | +₩0.1bn | +₩2.6bn |
| Chabiotech 차바이오텍 | 085660 | KOSDAQ | ₩1T ($0.5B) | 7.26% | – | +₩0.6bn | ₩-0.1bn | ₩-4.1bn | $-3M | +₩0.3bn | +₩3.8bn |
| HK inno.N HK이노엔 | 195940 | KOSDAQ | ₩1T ($0.8B) | 11.45% | 9.9× | +₩0.7bn | ₩-1.1bn | ₩-4.3bn | $-3M | ₩-3.3bn | +₩7.1bn |
| Classys 클래시스 | 214150 | KOSDAQ | ₩2T ($1.3B) | 68% | 9.2× | +₩0.4bn | +₩1.8bn | ₩-4.4bn | $-3M | ₩-3.1bn | +₩7.0bn |
| Proteina 프로티나 | 468530 | KOSDAQ | ₩0T ($0.3B) | 2.34% | – | +₩1.1bn | +₩2.0bn | ₩-4.7bn | $-3M | +₩14.5bn | ₩-8.9bn |
| Seers 씨어스 | 458870 | KOSDAQ | ₩1T ($0.7B) | 4.15% | 11.5× | +₩3.1bn | +₩2.2bn | ₩-4.7bn | $-3M | ₩-4.4bn | +₩9.1bn |
| Oscotec 오스코텍 | 039200 | KOSDAQ | ₩1T ($1.0B) | 12.23% | 13.9× | +₩2.1bn | +₩0.8bn | ₩-5.1bn | $-4M | +₩20.4bn | ₩-14.7bn |
| Inventage Lab 인벤티지랩 | 389470 | KOSDAQ | ₩0T ($0.2B) | 9.62% | – | +₩1.5bn | +₩1.3bn | ₩-6.0bn | $-4M | ₩-5.6bn | +₩11.9bn |
| Livs Med 리브스메드 | 491000 | KOSDAQ | ₩1T ($0.8B) | 3.02% | – | ₩-1.7bn | ₩-1.4bn | ₩-6.3bn | $-5M | ₩-4.3bn | +₩9.8bn |
| Ab Clon 앱클론 | 174900 | KOSDAQ | ₩0T ($0.4B) | 6.94% | – | ₩-0.2bn | ₩-0.2bn | ₩-7.2bn | $-5M | +₩6.4bn | +₩0.2bn |
| Immune Oncia Therapeutics 이뮨온시아 | 424870 | KOSDAQ | ₩0T ($0.2B) | 0.9% | – | +₩0.7bn | +₩0.9bn | ₩-7.6bn | $-6M | ₩-4.2bn | +₩11.6bn |
| Curiox Biosystems 큐리옥스바이오시스템즈 | 445680 | KOSDAQ | ₩1T ($0.9B) | 6.05% | – | +₩2.6bn | ₩-1.9bn | ₩-7.8bn | $-6M | +₩7.1bn | ₩-2.2bn |
| G2gbio 지투지바이오 | 456160 | KOSDAQ | ₩1T ($0.4B) | 5.5% | – | +₩0.5bn | +₩4.3bn | ₩-8.2bn | $-6M | +₩8.7bn | ₩-0.6bn |
| Rznomics 알지노믹스 | 476830 | KOSDAQ | ₩1T ($0.5B) | 8.18% | – | +₩3.5bn | ₩-1.6bn | ₩-8.3bn | $-6M | ₩-9.2bn | +₩18.4bn |
| April Bio 에이프릴바이오 | 397030 | KOSDAQ | ₩0T ($0.3B) | 8.78% | – | +₩1.5bn | +₩4.7bn | ₩-9.1bn | $-7M | ₩-2.5bn | +₩11.7bn |
| Samsung Epis Holdings 삼성에피스홀딩스 | 0126Z0 | KOSPI | ₩8T ($6.1B) | 4.94% | 25.3× | +₩8.4bn | ₩-10.7bn | ₩-10.3bn | $-8M | +₩3.4bn | +₩5.4bn |
| Dong Kook Pharmaceutical 동국제약 | 086450 | KOSDAQ | ₩1T ($0.9B) | 9.5% | 12.4× | +₩0.8bn | ₩-2.1bn | ₩-18.6bn | $-14M | +₩41.9bn | ₩-27.2bn |
| Hanmi Science 한미사이언스 | 008930 | KOSPI | ₩3T ($2.4B) | 0.87% | 18.7× | +₩1.4bn | +₩3.7bn | ₩-19.2bn | $-14M | +₩16.8bn | +₩1.0bn |
| Lunit 루닛 | 328130 | KOSDAQ | ₩1T ($0.7B) | 7.52% | – | +₩2.4bn | ₩-2.7bn | ₩-22.8bn | $-17M | +₩13.3bn | +₩9.1bn |
| Mezzion Pharma 메지온 | 140410 | KOSDAQ | ₩2T ($1.4B) | 22.36% | – | ₩-0.5bn | +₩1.7bn | ₩-25.7bn | $-19M | ₩-1.6bn | +₩26.6bn |
| Voronoi 보로노이 | 310210 | KOSDAQ | ₩2T ($1.7B) | 5.45% | – | ₩-1.9bn | ₩-6.7bn | ₩-26.6bn | $-20M | +₩0.1bn | +₩24.0bn |
| SK Biopharmaceuticals SK바이오팜 | 326030 | KOSPI | ₩6T ($4.3B) | 11.66% | 14.7× | +₩3.2bn | +₩3.3bn | ₩-30.6bn | $-23M | +₩3.3bn | +₩26.3bn |
| Olix Pharmaceuticals 올릭스 | 226950 | KOSDAQ | ₩2T ($1.7B) | 9.49% | – | +₩2.3bn | ₩-6.4bn | ₩-31.9bn | $-24M | +₩61.2bn | ₩-22.7bn |
| Hugel 휴젤 | 145020 | KOSDAQ | ₩2T ($1.7B) | 56.97% | 11.9× | +₩2.4bn | +₩6.1bn | ₩-37.9bn | $-28M | ₩-5.9bn | +₩41.6bn |
| L&c Bio 엘앤씨바이오 | 290650 | KOSDAQ | ₩2T ($1.4B) | 20.5% | 55.1× | ₩-0.9bn | ₩-35.7bn | ₩-63.8bn | $-47M | +₩4.8bn | +₩56.5bn |
| Hanmi Pharm 한미약품 | 128940 | KOSPI | ₩5T ($3.8B) | 12.69% | 23.8× | +₩1.3bn | +₩57.7bn | ₩-77.1bn | $-57M | +₩93.5bn | ₩-10.9bn |
| Sam Chun Dang Pharm 삼천당제약 | 000250 | KOSDAQ | ₩5T ($3.6B) | 2.73% | – | +₩3.1bn | ₩-27.6bn | ₩-105.5bn | $-78M | +₩13.6bn | +₩84.2bn |
| HLB HLB | 028300 | KOSDAQ | ₩6T ($4.1B) | 12.97% | – | +₩3.5bn | ₩-5.4bn | ₩-164.1bn | $-122M | ₩-13.4bn | +₩175.7bn |
| Samsung Biologics 삼성바이오로직스 | 207940 | KOSPI | ₩60T ($44.6B) | 12.83% | 27.7× | ₩-57.8bn | ₩-123.2bn | ₩-261.8bn | $-195M | +₩115.4bn | +₩134.5bn |
Positive = net buying, negative = net selling, in Korean won (₩bn) with USD at ₩1345.9/$. Flows aggregate the KRX main board and the NXT venue. Foreign ownership is KRX's foreign holdings divided by listed shares, one session behind. The group is the site's "Biotech & Pharma" classification, covering the largest companies by market cap.